A Study of Intravenous Iron Isomaltoside 1000 (MonoferÂ®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.
Non-myeloid Malignancies|Chemotherapy Induced Anaemia
DRUG: iron isomaltoside 1000|DRUG: iron sulphate
Change in Hb Concentration, Baseline week 4
Change in Hemoglobin From Baseline to Week 24, 24 weeks
The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.